Top 3 Undervalued Small Caps With Insider Buys To Watch In United States August 2024
In This Article:
The market is up 4.5% in the last 7 days, with all sectors gaining ground. In the last year, the market has climbed 22%, and earnings are forecast to grow by 15% annually. Identifying undervalued small-cap stocks with insider buying can offer unique opportunities for investors looking to capitalize on these favorable conditions.
Top 10 Undervalued Small Caps With Insider Buying In The United States
| Name | PE | PS | Discount to Fair Value | Value Rating |
|---|---|---|---|---|
| Columbus McKinnon | 20.2x | 0.9x | 44.38% | ★★★★★★ |
| PCB Bancorp | 10.9x | 2.8x | 43.21% | ★★★★★☆ |
| AtriCure | NA | 2.6x | 43.47% | ★★★★★☆ |
| Titan Machinery | 3.7x | 0.1x | 35.91% | ★★★★★☆ |
| Lindblad Expeditions Holdings | NA | 0.6x | 49.59% | ★★★★★☆ |
| Citizens & Northern | 12.5x | 2.8x | 45.04% | ★★★★☆☆ |
| Franklin Financial Services | 9.6x | 1.9x | 40.06% | ★★★★☆☆ |
| MYR Group | 33.5x | 0.5x | 43.28% | ★★★☆☆☆ |
| Community West Bancshares | 18.7x | 2.9x | 42.25% | ★★★☆☆☆ |
| Alta Equipment Group | NA | 0.1x | -55.56% | ★★★☆☆☆ |
We'll examine a selection from our screener results.
AtriCure
Simply Wall St Value Rating: ★★★★★☆
Overview: AtriCure specializes in developing and selling surgical and medical equipment, with a market cap of approximately $2.13 billion.
Operations: AtriCure generates revenue from its surgical and medical equipment segment, amounting to $429.95 million. The company's gross profit margin has been observed at 74.84%, with operating expenses primarily driven by R&D and general & administrative costs, totaling $356.58 million in the latest period.
PE: -27.3x
AtriCure, a small-cap company in the medical device sector, recently reported Q2 2024 sales of US$116.27 million, up from US$100.92 million a year ago, though net loss widened to US$8.01 million. They filed a shelf registration for $39.6 million and received regulatory approval in China for their AtriClip? device. Insider confidence is evident with recent share purchases by executives throughout July 2024, signaling potential optimism despite the company's unprofitability and reliance on external borrowing for funding.
-
Dive into the specifics of AtriCure here with our thorough valuation report.
-
Explore historical data to track AtriCure's performance over time in our Past section.
Dave
Simply Wall St Value Rating: ★★★★★☆
Overview: Dave operates a service-based and transaction-based financial technology platform with a market cap of $0.35 billion.
Operations: The company generates revenue primarily from service-based and transaction-based operations, with recent quarterly revenue reaching $292.68 million. Notably, the gross profit margin has shown an upward trend, rising to 57.03% as of the latest period ending June 30, 2024. Operating expenses have been a significant cost factor, with sales and marketing expenses being a major component.